Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038024 · ClinicalTrials.gov registry record · NA
Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage
A NA study of Cancer, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01038024: Completed NA study of Cancer, sponsored by Roswell Park Cancer Institute.
NCT01038024 is a NA study of Cancer that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 38 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01038024, a NA study of Cancer, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the basis for the reported good effects of antioxidant supplementation. A blood test using Mass Spectrometry will measure DNA damage which is expected to decrease with antioxidant administration and therefore decrease the risk of cancer.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT 1 tablet composed of antioxidants and minerals
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-07 |
| Phase | NA |
What the finished NCT01038024 record still lists
NCT01038024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which 1 tablet composed of antioxidants and minerals is the first listed.
NCT01038024 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01038024 about?
NCT01038024 is a clinical study titled "Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage". The purpose of this study is to evaluate the basis for the reported good effects of antioxidant supplementation. A blood test using Mass Spectrometry will measure DNA damage which is expected to decrease with antioxidant administration and therefore decrease the risk of cancer.
What is the current status of trial NCT01038024?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2010-01. Estimated completion is 2012-07.
What conditions does trial NCT01038024 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01038024?
The interventions under investigation include: 1 tablet composed of antioxidants and minerals (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01038024?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01038024 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01038024's enrollment target sits among peer trials
38 476th of 615 higher than 135 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
- NCT04237623 · 38 participants · Phase 2
GM-CSF With Post-Transplant Cyclophosphamide
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia